| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
The specific target of 2,6-Dimethyl-L-tyrosine is not a single receptor, but its primary role is as a structural component of opioid peptides. When incorporated into these peptides, the Dmt residue significantly increases their affinity for opioid receptors, particularly the mu-opioid receptor. This leads to enhanced analgesic activity. The compound itself is not a drug but a key pharmacophore for designing more potent pain-relieving peptides.
|
|---|---|
| ln Vitro |
In vitro, 2,6-Dimethyl-L-tyrosine is used to synthesize opioid peptide analogs with improved receptor binding affinity. The incorporation of Dmt into peptides like endomorphins and dermorphins has been shown to increase their potency in receptor binding assays. Specific IC50 values for the compound itself are not applicable; its value is demonstrated by the enhanced activity of the peptides it comprises.
|
| ln Vivo |
In vivo, 2,6-Dimethyl-L-tyrosine enhances the analgesic effects of opioid peptides. Studies have shown that Dmt-containing opioid peptide analogs exhibit potent antinociceptive activity in animal models of pain. This demonstrates the compound's utility in developing new, more effective analgesic drugs. Specific dosing and efficacy data depend on the final peptide analog.
|
| Enzyme Assay |
A cell-free assay for 2,6-Dimethyl-L-tyrosine is not applicable as it is not an enzyme inhibitor. Its interaction with opioid receptors is assessed through its incorporation into peptide ligands. Receptor binding affinity of the resulting peptides is measured using radioligand displacement assays with membrane preparations expressing the target receptors.
|
| Cell Assay |
Cellular assays for 2,6-Dimethyl-L-tyrosine are not conducted on the compound itself. Its effects are studied through the opioid peptides it helps constitute. These peptides are tested in cell-based assays to measure their ability to activate opioid receptors and downstream signaling pathways, such as inhibition of cAMP accumulation.
|
| Animal Protocol |
In vivo animal experiments for 2,6-Dimethyl-L-tyrosine are not conducted on the compound itself. Its effects are evaluated through the opioid peptides it helps constitute. These peptides are typically administered via various routes (e.g., intracerebroventricular, intravenous) to animal models to assess their analgesic efficacy in standard pain tests like the tail-flick or hot-plate assays.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable for 2,6-Dimethyl-L-tyrosine as a standalone compound. Its properties are studied within the context of the opioid peptides it modifies. These peptides may have different PK profiles depending on their structure. The compound is a solid with a molecular weight of 209.25 g/mol.
|
| Toxicity/Toxicokinetics |
Toxicity data for 2,6-Dimethyl-L-tyrosine are not provided in the available sources. As a tyrosine derivative used in research, it should be handled with standard laboratory safety precautions. It is intended for research use only and is not for human consumption.
|
| References | |
| Additional Infomation |
2,6-Dimethyl-L-tyrosine (CAS: 123715-02-6) is a tyrosine analogue that enhances the receptor affinity and in vivo analgesic effects of opioid peptides. Its synonyms include Dmt. The compound is a valuable tool in medicinal chemistry for the development of potent and selective analgesic peptides. It is not an approved drug and is strictly for research purposes.
|
| Molecular Formula |
C11H15NO3
|
|---|---|
| Molecular Weight |
209.2417
|
| Exact Mass |
209.105
|
| CAS # |
123715-02-6
|
| PubChem CID |
124247
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
412.8±45.0 °C at 760 mmHg
|
| Flash Point |
203.4±28.7 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.592
|
| LogP |
1.3
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
15
|
| Complexity |
220
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
OC1C=C(C)C(=C(C)C=1)C[C@@H](C(=O)O)N
|
| InChi Key |
LSNDLIKCFHLFKO-JTQLQIEISA-N
|
| InChi Code |
InChI=1S/C11H15NO3/c1-6-3-8(13)4-7(2)9(6)5-10(12)11(14)15/h3-4,10,13H,5,12H2,1-2H3,(H,14,15)/t10-/m0/s1
|
| Chemical Name |
(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7792 mL | 23.8960 mL | 47.7920 mL | |
| 5 mM | 0.9558 mL | 4.7792 mL | 9.5584 mL | |
| 10 mM | 0.4779 mL | 2.3896 mL | 4.7792 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
